News

In a recent study published in the Journal of Clinical Investigation, a team of researchers from the Boston University School of Medicine (BUSM) discovered a treatment breakthrough for total body scarring of the skin that occurs in patients with systemic sclerosis (SSc). The condition for which currently there…

In a recent study published in the journal Arthritis Research & Therapy, a team of researchers from Germany uncovered new insights into PAH detection in Scleroderma patients, determining that PH-screening using echocardiography in systemic sclerosis patients should be performed at rest and during exercise. Pulmonary hypertension (PH) is…

Autoimmune conditions can sometimes come in pairs, and it appears that individuals for systemic sclerosis (SSc) may also be at a risk for antiphospholipid antibody syndrome. A study from the Clinical Immunology Department of Colentina Clinical Hospital in Romania identified that patients with SSc commonly express antiphospholipid antibodies, although not…

According to a study recently presented at the Annual European Congress of Rheumatology (EULAR), Rome, patients with systemic sclerosis harbor a unique microbiome in their gut when compared to healthy individuals, which may contribute to patients’ immune dysfunction. Systemic sclerosis, also known as scleroderma, is an autoimmune disease (autoimmune diseases…

A investigational drug being developed by Corbus Pharmaceuticals Holding, Inc. to treat systemic sclerosis was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The drug that received the status, resunab, is Corbus’ lead drug candidate, as the company is focused on…

A study recently presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, Italy, June 10-13 revealed that individuals with systemic sclerosis have a unique bacterial signature in their colon that is different from healthy individuals. Systemic sclerosis, also known as scleroderma, is a rare, chronic…

It’s a breakthrough: Roche has been awarded breakthrough therapy designation status for its ACTEMRA®/RoACTEMRA® (tocilizumab) treatment in patients with systemic sclerosis. The designation will enable Roche to speed up development and review of its treatment to help bring systemic sclerosis patients this new treatment as soon as possible. “Close to…

Algerian researchers have shed further light on the co-existence of hypertension in scleroderma and what it could mean to the progression of the disorder. Scleroderma is chronic hardening of the skin and connective tissues that occurs in the condition systemic sclerosis. Hypertension is another frequent symptom of the disease, one that…

Recently, a group of researchers from University of British Columbia in Vancouver, Canada released study results in which they found that mortality risk prediction models used to clinically assess the 1-year survival rate for patients with idiopathic pulmonary fibrosis (IPF), could also be utilized to accurately predict short-term mortality in patients…

Three leading organizations focused on scleroderma advocacy and research are partnering during June’s Scleroderma Awareness Month in order to boost awareness and compassion for those who suffer from the disease and their families. The Scleroderma Foundation, Scleroderma Research Foundation and Scleroderma Society of Canada are the primary partners in the effort. This…